Berlin: BioNTech-Pfizer claims its Covid-19 vaccine to be 100% effective on children between 12 and 15 years old. The company is hoping to get the approval of vaccination for the children before the next school session. In a statement released on Wednesday by the company, it said that Phase-3 trial was conducted in 2,260 juveniles in the US and proved to be 100% effective and showed strong antibody response.
“We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year,” said Pfizer chief executive Albert Bourla.
The chief executive of German company BioNTech, Ugur Sahin, said the results showing high protection for teens were “very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant”.
The BioNTech-Pfizer shot is based on novel mRNA technology and was the first COVID-19 vaccine to be approved in the West late last year.
Both the United States and the European Union have approved its use for people aged 16 and above.
